Examples: histone, BN000065

Project: PRJNA816330

Triple-negative breast cancer (TNBC) often develops resistance to single-agent treatment, which can be circumvented using targeted combinatorial approaches. Here, we demonstrate that the simultaneous inhibition of LOXL2 and BRD4 synergistically limits TNBC proliferation in vitro and in vivo. Mechanistically, LOXL2 interacts in the nucleus with the short isoform of BRD4 (BRD4S), MED1, and the cell cycle transcriptional regulator B-MyB. These interactions sustain the formation of BRD4 and MED1 nuclear transcriptional foci and control cell cycle progression at the gene expression level. The pharmacological co-inhibition of LOXL2 and BRD4 reduces BRD4 nuclear foci, BRD4-MED1 colocalization, and the transcription of cell cycle genes, thus supressing TNBC cell proliferation. Finding novel strategies to disrupt BRD4S-LOXL2 interaction holds potential for developing successful TNBC therapies. Overall design: mRNA (triplicates), ATAC-seq (triplicates) and ChIP-seq of BRD4L/S (AB antibody) (duplicates) and BRD4L (BB antibody) (single replicate) in control and LOXL2 downregulated conditions in MDA-MB-231 cells.

General